MIM
GBT

MetLife Investment Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

MetLife Investment Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-33,813
Closed -$2.3M – 2879
2022
Q3 		$2.3M Buy
33,813
+641
+2% +$35.4K 0.02% 820
2022
Q2 		$1.06M Sell
33,172
-1,231
-4% -$36K 0.01% 1175
2022
Q1 		$1.19M Buy
34,403
+12,697
+58% +$380K 0.01% 1219
2021
Q4 		$635K Hold
21,706
– – 0.01% 1382
2021
Q3 		$553K Hold
21,706
– – 0.01% 1465
2021
Q2 		$760K Buy
+21,706
New +$847K 0.01% 1328
2020
Q2 		– Sell
-24,047
Closed -$1.23M – 2378
2020
Q1 		$1.23M Sell
24,047
-1,343
-5% -$90K 0.02% 814
2019
Q4 		$2.02M Hold
25,390
– – 0.02% 813
2019
Q3 		$1.23M Buy
25,390
+958
+4% +$49.9K 0.01% 971
2019
Q2 		$1.29M Buy
24,432
+1,335
+6% +$76.7K 0.01% 1003
2019
Q1 		$1.22M Hold
23,097
– – 0.01% 998
2018
Q4 		$948K Hold
23,097
– – 0.01% 1038
2018
Q3 		$878K Hold
23,097
– – 0.01% 1200
2018
Q2 		$1.04M Buy
23,097
+5,516
+31% +$251K 0.01% 1002
2018
Q1 		$849K Hold
17,581
– – 0.01% 1076
2017
Q4 		$692K Buy
+17,581
New +$657K 0.01% 1211

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

MetLife Investment Management's GBT Position: Q4 2022 in Review

MetLife Investment Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 33,813 shares — an estimated $2.3M sold.

MetLife Investment Management first reported a position in GBT in Q4 2017 and held it in 16 quarters. The position peaked at $2.3M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • MetLife Investment Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • MetLife Investment Management sold 33,813 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $2.3M.
  • MetLife Investment Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2017 and held it in 16 quarters.
  • MetLife Investment Management's Global Blood Therapeutics, Inc. position peaked at $2.3M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on MetLife Investment Management's 13F filing for Q4 2022, filed 15 Feb 2023.